SERPINF2抗体;SERPINF2 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human normal stomach tissue, Primary antibody: P11450(SERPINF2 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11450(SERPINF2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

SERPINF2. also known as alpha-2-antiplasmin (A2AP), is a serine protease inhibitor primarily synthesized in the liver and megakaryocytes. It plays a critical role in regulating fibrinolysis by irreversibly inhibiting plasmin, the key enzyme responsible for breaking down blood clots. SERPINF2 binds to plasmin, forming a stable complex that prevents excessive fibrin degradation, thereby maintaining a balance between coagulation and fibrinolysis. Deficiencies in SERPINF2. though rare, are linked to a bleeding disorder characterized by delayed clot lysis and prolonged hemorrhage. Conversely, elevated levels have been associated with thrombotic conditions due to impaired fibrinolysis.

SERPINF2 antibodies are essential tools in biomedical research and diagnostics. They enable the detection and quantification of SERPINF2 in plasma or tissue samples via techniques like ELISA, Western blotting, or immunohistochemistry. These antibodies aid in studying SERPINF2's physiological roles, its interactions with plasmin, and its involvement in pathological conditions such as bleeding disorders, thrombosis, or liver diseases. Commercial SERPINF2 antibodies are typically developed in hosts like rabbits or mice, targeting specific epitopes with validated specificity. Recent studies also explore their therapeutic potential, such as modulating SERPINF2 activity to manage clotting abnormalities. Understanding SERPINF2 dynamics through antibody-based assays continues to advance insights into hemostatic disorders and therapeutic strategies.